An Australian stem cell and regenerative medicine company
About Us
About Us
What We Do
Board Of Directors
Management
Scientific Advisors
Corporate Governance
Company History
Clinical Development
Graft-versus-host-disease
Osteoarthritis
Acute respiratory distress syndrome
Diabetic Wounds
Renal transplantation
Pre-clinical Development
Asthma
Heart Attack
Coronary Artery Disease
Brain Cancer
Sepsis
Critical Limb Ischemia
Idiopathic pulmonary fibrosis
Science & Technology
Cymerus Technology
About MSCs
About iPSCs
Science Publications
Investors
Stock Information
ASX Announcements
Financial Reports
Presentations
Corporate Governance
Analyst Research
Investor FAQs
Right to Receive Documents
Newsroom
FAQ
Company FAQs
Investor FAQs
Contact Us
ASX Announcements
18 Jan 2021
Completion of Entitlement Offer and Shortfall Placement
11 Jan 2021
Entitlement Offer – Closing Date Reminder
31 Dec 2020
Cleansing Notice
30 Dec 2020
Appnedix 2A
30 Dec 2020
2020 Review and Outlook
29 Dec 2020
Becoming a substantial holder
24 Dec 2020
Cleansing Notice
23 Dec 2020
Appendix 2A
21 Dec 2020
Letter to Ineglible Shareholders
21 Dec 2020
Offer Booklet and Entitlement & Acceptance Form
21 Dec 2020
Cynata Entitlement Offer Opens
21 Dec 2020
Cleansing Notice
18 Dec 2020
Cynata provides update on Placement and Appendix 2A
15 Dec 2020
Letter to Optionholders
11 Dec 2020
Notice Under Section 708AA of the Corporations Act
11 Dec 2020
Investor Presentation
11 Dec 2020
Proposed Issue of Securities
11 Dec 2020
CYP Closes $15m Institutional Placement to Expand Pipeline
30 Nov 2020
Appendix 3Ys x 5
30 Nov 2020
Appendix 3G
24 Nov 2020
Replacement Constitution
24 Nov 2020
Results of Annual General Meeting
24 Nov 2020
AGM Presentations
18 Nov 2020
Cynata Technology Featured on Front Cover of Nature Medicine
11 Nov 2020
Phase 3 Osteoarthritis Clinical Trial Commences
30 Oct 2020
Quarterly Activity Report & Appendix 4C
29 Oct 2020
AusBiotech Conference Presentation
23 Oct 2020
Annual Report to Shareholders
23 Oct 2020
Letter to Shareholders, Notice of AGM & Proxy Form
06 Oct 2020
Date of AGM & Closing Date for Director Nominations
24 Sep 2020
Potential Utility of Cymerus MSCs in Heart Attack Model
15 Sep 2020
Cynata Clinical Trial Results Published in Nature Medicine
14 Sep 2020
Appendix 3G
07 Sep 2020
Cymerus MSCs Effective in Preclinical Lung Disease Study
25 Aug 2020
Appendix 4E & Annual Report
24 Aug 2020
Patient Enrolment Opens in COVID-19 Clinical Trial
19 Aug 2020
Appendix 3G
18 Aug 2020
Cynata Appoints Dr Geoff Brooke as Chairman
14 Aug 2020
Cynata Investor Presentation
07 Aug 2020
Notice of Allowance from Korean Patent Office
05 Aug 2020
Notification of Expiry of Unlisted Options
30 Jul 2020
Cynata Announces Positive Results from GvHD Trial Follow-up
28 Jul 2020
Quarterly Activity Report & Appendix 4C
20 Jul 2020
Notification of Expiry of Unlisted Options
01 Jul 2020
Securities Dealing Policy
01 Jul 2020
Final Director's Interest Notice
24 Jun 2020
Appendix 3Y-Dr Geoff Brooke
18 Jun 2020
Ethics Approval & Expedited Pathway for Phase 3 OA Trial
16 Jun 2020
Appendix 3X-Darryl Maher
16 Jun 2020
Appendix 3Y-Ross Macdonald
‹
1
2
3
4
5
6
7
8
9
10
11
›